-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Introduction: Customized penis transplantation is implemented in the UK; The world's first new drug to delay the onset of type 1 diabetes was approved; Rongcan Biotech completed tens of millions of yuan pre-A round financing.
.
.
.
.
.
BioDiscovery pays attention to "medicine" with you and explores the value of biotechnology!
01
Custom penis transplantation is implemented in the UK
Recently, University College London (ULC) achieved a custom-sized penis transplant.
The patient who received the transplant was 47-year-old Malcom MacDonald
.
In 2014, Malcom underwent testicular and penile resection with irreversible testicular decay due to sepsis, which caused his fingers
, toes and penis to darken.
To ease Malcom's pain, the National Society for Organisational Technology funded £50,000 to grow and transplant a new penis
from Malcom's arm.
After communicating with David Ralph, a penis construction expert at University College London, Malcom requested that the new penis be customized to be 15cm in size, which is 5cm
longer than before.
Doctors removed a flap from his left arm, rolled it up to form a temporary penis, and created a urethra
inside.
Due to intraoperative hypoxemia, the new penis must be connected to the blood vessels in the arm to keep the tissue healthy
.
After the penis has grown in the arm for some time, the doctor successfully transplants it into the patient's groin
.
According to doctors, the transplanted new penis allowed Malcom to regain sexual function and urinary capacity
.
02
The world's first delay
New drug for type 1 diabetes attack approved
On November 18, the US FDA announced that it had approved Provention Bio's drug Tzield (teplizumab) for the purpose of delaying the disease progression
in specific high-risk groups of type 1 diabetes.
The US FDA press release pointed out that this is also the first drug
that can delay the onset of type 1 diabetes.
Type 1 diabetes is a chronic disease
.
Due to damage to the patient's pancreatic β cells, the amount of insulin they secrete in their bodies is very small, even almost zero! Insulin is an important hormone in the body, and insufficient secretion can lead to abnormal increases in blood sugar levels and abnormal glucose metabolism, inducing a series of metabolic problems
.
teplizumab is an anti-CD3 monoclonal antibody that promises to stop attacking insulin-producing cells by binding to specific immune cells
.
Previous studies showed that the proportion of patients at high risk of type 1 diabetes who received teplizumab reached 50% at a median follow-up of 2.
5 years, more than twice as much as the placebo group (22%) (HR=0.
457, P=0.
01).
In addition, studies have shown that teplizumab treatment significantly improves the function of pancreatic islet β cells, as well as the ability to
secrete insulin.
03
Rongcan Biotech completed tens of millions of yuan
RMB Pre-A round of financing
Recently, Rongcan Biotechnology, an independent innovation platform enterprise of nucleic acid technology, announced the completion of tens of millions of yuan in pre-A round of financing, which was led by well-known medical and health professional funds
.
This round of financing will help Rongcan Biotech accelerate product development and team building, and promote the leading pipeline into clinical research
.
Rongcan Biotech was founded in June 2020 by senior returnee doctors and a team of domestic experts, the founding team has decades of experience in the nucleic acid industry, has successfully designed and developed LNP carriers with completely independent intellectual property rights, and co-signed with Professor Robert Langer, obtained a new cationic lipid carrier patent authorization in the United States (the founder of Rongcan is the first inventor), and is also one of the few teams in China to jointly develop cationic lipid carriers with Professor Robert Langer and obtain US patent authorization
。
04
Freeline sells subsidiary
Stop hemophilia B gene therapy
Recently, Freeline Therapeutics (Freeline) made three major moves to cut expenses and find gene therapy partners: sell subsidiaries, stop investment in hemophilia B gene therapy, and lay off employees, so as to retain enough funds to maintain operations until 2024
.
Founded in 2015 and based in Stevenage, UK, Freeline Therapeutics is a pioneer in gene therapy for rare diseases
.
Its therapy is based on a next-generation proprietary AAV vector platform, and its leading plan is gene therapy
for hemophilia B.
05
Southern Yuan Medicine
Tens of millions in pre-A round financing
Recently, Nanjing Nanfang Yuan Biotechnology Co.
, Ltd.
(hereinafter referred to as Southern Yuan), an innovative platform for the development and production of functional polysaccharides, received tens of millions of yuan in pre-A round financing, led by Suzhou Yanying Investment Management Co.
, Ltd.
and followed by Changzhou Zhengkaifeng Venture Capital Partnership
.
The amount of financing in this round is planned to be used for raw material preparation, quality system construction and product preclinical research
.
Southern Yuan was established in January 2022 and received angel round financing
of about RMB 10 million during the same period.
Its founder team has more than 30 years of academic research, drug development and industrialization experience in the field of functional polysaccharides and metabolic drugs, and has published more than 100 Class I scientific papers
.